South African pharma tycoon Stephen Saad, who leads Aspen Pharmacare Holdings, Africas largest drugmaker, says he wouldnt be surprised if the companys new weight-loss product tops 50 million in sales within two years. His confidence comes as Aspen secures regulatory approval to launch an injector pen version of Mounjaro in South Africa.
The pen format is designed to make the blockbuster GLP-1 drug easier for patients to use, following its initial rollout in vials for Type 2 diabetes last December. The move places Aspen in more direct competition with Novo Nordisk, whose own GLP-1 drugs have been reshaping the fast-growing diabetes and weight-loss market.
Stephen Saad bets big on Mounjaro